Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30622634 | 1.00 | HTR2A (0.46) | HTR2AHRH1CDK8CDK5CCKBR | |
| SCHEMBL26639717 | 1.00 | HTR2A (0.46) | HTR2AHRH1CDK8CDK5CCKBR | |
| SCHEMBL26639714 | 1.00 | HTR2A (0.46) | HTR2AHRH1CDK8CDK5CCKBR | |
| SCHEMBL8649621 | 0.90 | HTR2A (0.49) | HTR2AHRH1CCKBRBCHE | |
| SCHEMBL13192556 | 0.86 | BCHE (0.39) | BCHE | |
| SCHEMBL1031433 | 0.83 | HTR2A (0.43) | HTR2AHRH1CCKBR | |
| SCHEMBL8261364 | 0.81 | HTR5A (0.41) | CCKBRBCHE | |
| SCHEMBL11734757 | 0.80 | CDK8 (0.52) | HTR2AHRH1CDK8CDK5RET | |
| SCHEMBL31377482 | 0.78 | TACR2 (0.38) | HTR2A | |
| SCHEMBL11642624 | 0.78 | CDK8 (0.51) | HTR2AHRH1CDK8CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| EP-4511360-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Mindset Pharma Inc. (CA) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023201421-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2022117640-A1 | INHALABLE FORMULATIONS | SMALL PHARMA LTD (GB) | 2022-06-09 | — | — | WO | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353827-A1 | INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, TPH2, HTR5A | HTR2A 5/4885HRH1 425/4885CDK8 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.